GlassScriptPhysician profile
Whitney E Loganbill
NPI 1356764591
$2,091.82
in general payments reported to CMS, 2019-2025
21 companies · $807 in 2025
The $807 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $171 · 2023: $470 · 2024: $508 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $364.60 | 2022-2025 | Cuvitru, Hyqvia |
| Insmed, INC. | $330.31 | 2022-2025 | Arikayce |
| Abbvie INC. | $261.57 | 2021-2025 | |
| Melinta Therapeutics, LLC | $188.05 | 2022-2024 | Kimyrsa, Vabomere, Rezzayo |
| Hospira, INC. | $134.97 | 2024-2025 | |
| Grifols USA, LLC | $107.90 | 2023-2025 | Xembify |
| Tersera Therapeutics LLC | $69.32 | 2025 | Quzyttir |
| Gilead Sciences, INC. | $68.58 | 2022-2025 | Veklury |
| Csl Behring | $68.42 | 2022-2024 | Hizentra |
| Pfizer INC. | $67.15 | 2025 | |
| Merck Sharp & Dohme LLC | $65.41 | 2024-2025 | Pifeltro, Delstrigo, Prevymis |
| Aimmune Therapeutics, INC. | $62.51 | 2025 | Vowst |
| Astrazeneca Pharmaceuticals LP | $51.56 | 2022-2023 | Evusheld |
| Invivyd INC | $47.06 | 2025 | Pemgarda |
| Octapharma USA, INC. | $45.76 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $44.65 | 2023-2024 | Rebyota |
| Shionogi INC | $39.91 | 2023-2025 | Fetroja |
| Amgen INC. | $22.89 | 2025 | Krystexxa |
| La Jolla Pharmaceutical Company | $18.94 | 2025 | |
| Pharming Healthcare, INC. | $16.72 | 2022 | |
| Cormedix INC. | $15.54 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Loganbill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.